HHS Lets Compounding Pharmacies Make 6 Unapproved Peptides Under Enforcement Discretion

5.8 · 1d ago · US

The Facts

  • On Wednesday, Oct. 28, 2026, HHS filed a notice saying it will exercise 'enforcement discretion' and not take action against compounding pharmacies that make six unapproved peptides. ✓5 · NBC News, NPR, Ars Technica, CBS News, NY Times
  • None of the six peptides is FDA-approved, and the FDA's own scientists concluded there is insufficient evidence of safety and effectiveness. ✓4 · NBC News, NPR, CBS News, Ars Technica
  • The policy does not change the peptides' legal or regulatory status or grant FDA approval; it stays in place until the FDA finalizes a rule on compounded peptides, which the FDA has not yet proposed. ✓3 · NPR, Ars Technica, CBS News
  • An FDA advisory panel voted in July to recommend allowing compounding of the six peptides, against the recommendation of the FDA's own scientists. ✓3 · NBC News, NPR, CBS News
  • The six peptides are BPC-157, epitalon, KPV, MOTS-c, semax and TB-500. ✓2 · NBC News, CBS News
Dive deeper · 8 more factsShow less
  • Pharmacies must certify identity and purity of the ingredients and report serious side effects; the policy requires an FDA-registered ingredient maker, a lab certificate for raw ingredients, and patient-specific prescriptions. ✓2 · NBC News, CBS News
  • Public Citizen, the Partnership for Safe Medicines and the Center for Science in the Public Interest's Peter Lurie criticized the policy; the Alliance for Pharmacy Compounding welcomed it. ✓2 · NBC News, NPR
  • The policy applies to smaller 503A compounding pharmacies, not larger 503B outsourcing facilities. NPR only
  • The policy is titled 'Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances'; it was made available on the Federal Register Wednesday, with final publication set for Oct. 30. Ars Technica only
  • Public comment opens Friday and runs through Nov. 13. CBS News only
  • In 2023 the FDA removed the six peptides from the list of substances compounding pharmacies could use, citing safety concerns. Ars Technica only
  • The July advisory panel included six new appointees with ties to the peptide industry and one member who is the son of a U.S. representative who has pushed Kennedy on peptide access. NBC News only
  • Joshua Fritzler of Olympia and Wesley Pharmaceuticals said small 503A pharmacies will not be able to meet demand. NPR only

Context

The Department of Health and Human Services said it will not take enforcement action against compounding pharmacies that prepare six unapproved peptides, a step that lets pharmacies begin offering them before the FDA completes a formal rulemaking to add them to its approved bulk-substances list.

HHS says the policy gives patients an alternative to the 'research use only' gray market. The FDA's own scientists have said evidence of safety and effectiveness is insufficient. Consumer advocacy groups have criticized the move, while a pharmacy compounding trade group supports it.

Conflicting Reports

  • Outlets differ on the document's status: CBS News calls it a 'draft policy' open to public comment; NBC News, NPR and Ars Technica describe it as a notice or policy already issued, and Ars Technica calls it a 'rule'.

How the Agent Panel Scored This

Independent AI personas each scored importance 1–10; the story's score is a trimmed mean (highest and lowest votes dropped). Vote spread: 2.

7 Policy Expert HHS issued a formal enforcement discretion notice that concretely allows compounding pharmacies to make six unapproved peptides nationwide, a binding executive action affecting many patients and pharmacies despite not changing legal status.
6 News Editor HHS issued a concrete enforcement-discretion notice that lets compounding pharmacies begin offering six unapproved peptides to patients, affecting a meaningful number of patients and drawing significant controversy, though it does not change legal status and the impact is moderate and niche to a specialized drug segment.
6 Critical Reader HHS issued a concrete enforcement-discretion policy that lets compounding pharmacies make six unapproved peptides, affecting patients and the pharmacy sector, though it does not change legal status and is a moderate-scope regulatory action.
6 Business Analyst HHS enforcement discretion concretely allows pharmacies to make six unapproved peptides for patients, a regulatory shift affecting many patients and the compounding market, though it does not change legal status or grant approval, so it is moderate-to-significant rather than major breaking news.
6 Informed Citizen HHS issued a concrete enforcement-discretion policy letting compounding pharmacies sell six unapproved peptides to patients, affecting consumers and the pharmacy market, though it does not change legal status and the impact is contested and limited in scope to 503A pharmacies.
5 Global Affairs Analyst HHS issued a concrete enforcement-discretion policy allowing pharmacies to compound six unapproved peptides, a meaningful health-regulation shift affecting patients and the industry, but it is a niche FDA compounding policy rather than broad, immediate, widespread news.
5 Science & Tech Analyst HHS issued a concrete enforcement-discretion policy affecting compounding pharmacies and patient access to six unapproved peptides, a notable regulatory action with safety controversy, but it is limited to a specific niche of 503A pharmacies and does not change legal status.

Sources (7)

← All stories